TNFRSF9 and malignant colon neoplasm: ILA, as a ligand for AhR, has been confirmed to maintain the intestinal epithelial barrier and modulate immune function, with efficacy in mitigating intestinal ischemia–reperfusion injury, ulcerative colitis, and colon cancer [42, 55, 56].